A practical reference on lyophilised powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
常规纯度与身份确认依赖反相高效液相色谱，并辅以质谱测定分子量。氨基酸组成分析可用于验证序列构成，肽图分析则能进一步定位修饰或降解产物。杂质谱通常关注缺失序列肽、截短片段和氧化产物。不同方法的检出限并不相同，因此各实验室报告的纯度数值不宜直接横向比较。
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
== Selected publications == Góngora-Benítez M, Tulla-Puche J, Albericio F (2014). Multifaceted roles of disulfide bonds. Peptides as therapeutics. Chemical Reviews. doi:10.1021/Cr400031Z Subirós-Funosas R, Prohens R, Barbas R, El-Faham A, Albericio F (2010). Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. Chemistry (Weinheim An Der Bergstrasse, Germany). doi:10.1002/Chem.200900614 Ruiz-Sanchis P, Savina SA, Albericio F, Álvarez M. Structure, bioactivity and synthesis of natural products with hexahydropyrrolo[2,3-b]indole. Chemistry (Weinheim An Der Bergstrasse, Germany). doi:10.1002/Chem.201001451 El-Faham A, Albericio F (2011). Peptide coupling reagents, more than a letter soup. Chemical Reviews. 111: 6557-602. doi:10.1021/Cr100048W Isidro-Llobet A, Alvarez M, Albericio F (2009). Amino acid-protecting groups. Chemical Reviews. doi:10.1021/Cr800323S Bruckdorfer T, Marder O, Albericio F (2004). From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Current Pharmaceutical Biotechnology. doi:10.2174/1389201043489620
=== Effect of vigorous exercise === When running, breasts may move three-dimensionally: vertically, horizontally and laterally, in an overall figure-8 motion. Unrestrained movement of large breasts may contribute to sagging over time. Motion studies have revealed that when a woman runs, more than 50% of the breast's total movement is vertical, 22% is side-to-side, and 27% is in-and-out. A 2007 study found that encapsulation-type sports bras, in which each cup is separately molded, are more effective than compression-type bras, which press the breasts close to the body, at reducing total breast motion during exercise. Encapsulation bras reduce motion in two of the three planes, while compression bras reduce motion in only one plane. Previously, it was commonly believed that a woman with small- to medium-size breasts benefited most from a compression-type sports bra, and women with larger breasts needed an encapsulation-type sports bra.
== Medical uses == Hydroxyzine is used in the treatment of itchiness, anxiety, and nausea due to motion sickness. A systematic review concluded that hydroxyzine outperforms placebo in treating generalized anxiety disorder. Insufficient data were available to compare the drug with benzodiazepines and buspirone. Hydroxyzine can also be used for the treatment of allergic conditions, such as chronic urticaria, atopic or contact dermatoses, and histamine-mediated pruritus. These have also been confirmed in both recent and past studies to have no adverse effects on the liver, blood, nervous system, or urinary tract. Use of hydroxyzine for premedication as a sedative has no effects on tropane alkaloids, such as atropine, but may, following general anesthesia, potentiate meperidine and barbiturates, and use in pre-anesthetic adjunctive therapy should be modified depending upon the state of the individual. Doses of hydroxyzine hydrochloride used for sleep range from 25 to 100 mg. As with other antihistamine sleep aids, hydroxyzine is usually only prescribed for short term or "as-needed" use since tolerance to the central nervous system (CNS) effects of hydroxyzine can develop in as little as a few days. A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found little evidence to inform the use of hydroxyzine for insomnia. A 2023 meta-review concludes that hydroxyzine is effective for inducing sleep onset but less effective for maintaining sleep for eight hours.
Tividenofusp alfa, sold under the brand name Avlayah, is an enzyme replacement therapy used for the treatment of Hunter syndrome. Tividenofusp alfa is a hydrolytic lysosomal glycosaminoglycan-specific enzyme. The most common side effects include upper respiratory tract infection, ear infection, fever, anemia, cough, vomiting, diarrhea, rash, COVID-19, runny nose, nasal congestion, fall, headache, skin abrasion, and hives. Tividenofusp alfa was approved for medical use in the United States in March 2026.
Sources: en.wikipedia.org
The metalloids illustrate an organizing principle of the periodic table called a diagonal relationship. The diagonal positioning of the metalloids represents an exception to the observation that elements with similar properties tend to occur in vertical groups. A related effect can be seen in other diagonal similarities between some elements and their lower right neighbours, specifically lithium-magnesium, beryllium-aluminium, and boron-silicon. Rayner-Canham has argued that these similarities extend to carbon-phosphorus, nitrogen-sulfur, and into three d-block series. This relationship arises due to competing horizontal and vertical trends in the nuclear charge. Going along a period, the nuclear charge increases with atomic number as do the number of electrons. The additional pull on outer electrons as nuclear charge increases generally outweighs the screening effect of having more electrons. With some irregularities, atoms therefore become smaller, ionization energy increases, and there is a gradual change in character, across a period, from strongly metallic, to weakly metallic, to weakly nonmetallic, to strongly nonmetallic elements. Going down a main group, the effect of increasing nuclear charge is generally outweighed by the effect of additional electrons being further away from the nucleus. Atoms generally become larger, ionization energy falls, and metallic character increases. The net effect is that the location of the metal–nonmetal transition zone shifts to the right in going down a group.
Insulin-like growth factor 1 (IGF1), also called somatomedin C, is a hormone similar in molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults. In the 1950s IGF1 was called "sulfation factor" because it stimulated sulfation of cartilage in vitro, and in the 1970s due to its effects it was termed "nonsuppressible insulin-like activity" (NSILA). IGF1 is a protein that in humans is encoded by the IGF1 gene. IGF1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF1 has a molecular weight of 7,649 daltons. In dogs, an ancient mutation in IGF1 is the primary cause of the toy phenotype. IGF1 is produced primarily by the liver. Production is stimulated by growth hormone (GH). Most of IGF1 is bound to one of 6 binding proteins (IGF-BP). IGFBP-1 is regulated by insulin. IGF1 is produced throughout life; the highest rates of IGF1 production occur during the pubertal growth spurt. The lowest levels occur in infancy and old age. Low IGF1 levels are associated with cardiovascular disease, while high IGF1 levels are associated with cancer. Mid-range IGF1 levels are associated with the lowest mortality. A synthetic analog of IGF1, mecasermin, is used for the treatment of growth failure in children with severe IGF1 deficiency. Cyclic glycine-proline (cGP) is a metabolite of hormone insulin-like growth factor-1 (IGF1).
== Applications == Development of solid lipid nanoparticles is one of the fields of lipid nanotechnology (for a review on lipid nanotechnology, see ) with several potential applications in drug delivery, clinical medicine and research, as well as in other disciplines. Due to their size-dependent properties, lipid nanoparticles can possibly develop new therapeutics. The ability to incorporate drugs into nanocarriers offers a new prototype in drug delivery that could hold great promise for attaining bioavailability enhancement along with controlled and site-specific drug delivery. SLNs are also considered to be well tolerated in general, due to their composition from physiologically similar lipids. The conventional approaches such as use of permeation enhancers, surface modification, prodrug synthesis, complex formation and colloidal lipid carrier-based strategies have been developed for the delivery of drugs to intestinal lymphatics. In addition, polymeric nanoparticles, self-emulsifying delivery systems, liposomes, microemulsions, micellar solutions and recently, solid lipid nanoparticles (SLN) have been exploited as probable possibilities as carriers for oral intestinal lymphatic delivery.
=== α - cleavage === Fragmentation arises from a homolysis processes. This cleavage results from the tendency of the unpaired electron from the radical site to pair up with an electron from another bond to an atom adjacent to the charge site, as illustrated below. This reaction is defined as a homolytic cleavage since only a single electron is transferred. The driving forces for such reaction is the electron donating abilities of the radical sites: N > S, O,π > Cl, Br > H. An example is the cleavage of carbon-carbon bonds next to a heteroatom. In this depiction, single-electron movements are indicated by a single-headed arrow.
== History == MMDA was first synthesized and studied by Gordon Alles at the Edgewood Arsenal in the mid-1950s. Its Edgewood Arsenal code name is unknown. Subsequently, Alexander Shulgin synthesized MMDA in 1962 and discovered its psychoactive effects that same year. Shulgin published his findings on MMDA in the scientific literature in 1964. Use of MMDA in psychedelic-assisted psychotherapy was studied by Shulgin, Thornton Sargent, and Claudio Naranjo in the mid-1960s and their findings were published in 1973. Naranjo also described MMDA for these purposes in his 1973 book The Healing Journey: New Approaches to Consciousness. Shulgin subsequently further described MMDA in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.